Intensity Therapeutics, Inc. (NASDAQ: INTS) reported a net loss of $11.6 million for the year ended December 31 2025, a reduction of $4.7 million from the $16.3 million loss in 2024. The improvement was driven by a $2.8 million cut in clinical‑trial expenses and a $1.4 million decrease in research and development costs, reflecting tighter spending on the INVINCIBLE‑3 study and other early‑phase programs.
Cash and cash equivalents stood at $11.9 million as of December 31 2025, after the company raised more than $20 million in gross proceeds through two public offerings and an ATM issuance. The pro‑forma cash position of $13 million is projected to support operations through the second quarter of 2027, assuming current burn rates. The company also highlighted an unused $60 million ATM facility and a 1‑for‑25 reverse stock split completed on February 19 2026, which helped maintain Nasdaq listing compliance while preserving liquidity.
Clinically, Intensity plans to resume patient enrollment in its INVINCIBLE‑3 and INVINCIBLE‑4 trials once sufficient funding is secured. The company expects to present detailed results for seven Cohort A patients in the INVINCIBLE‑4 study at a future oncology conference and has amended the protocol to address skin irritation. Management noted that the company will continue treating enrolled patients and maintaining the database during the enrollment pause, while prioritizing a restart of site activations in 2026.
"Our data published in the Lancet’s eBioMedicine journal for the treatment of metastatic disease, and the results reported on the safety and efficacy in the INVINCIBLE‑4 study were promising and unique for a locally‑delivered oncology drug. With the capital raised in 2025 and an unused $60 million ATM facility in place, we intend to resume patient enrollment in both studies as soon as possible," said CEO Lewis H. Bender.
Investors highlighted the company’s strong liquidity and encouraging clinical data, but expressed concerns about dilution risk from the ATM program and valuation levels. The positive clinical progress in the INVINCIBLE‑4 study, combined with the extended runway, supports a cautiously optimistic view of Intensity’s near‑term prospects.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.